Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Authors:
- David RoofehDRDavid Roofeh
- Ella A KazerooniEKElla A Kazerooni
- Donald TashkinDTDonald Tashkin
- Shervin AssassiSAShervin Assassi
- Fernando MartinezFMFernando Martinez
- Athol U WellsAWAthol U Wells
- Ganesh RaghuGRGanesh Raghu
- Christopher P DentonCDChristopher P Denton
- Lorinda ChungLCLorinda Chung
- Anna-Maria Hoffmann-VoldAHAnna-Maria Hoffmann-Vold
- Oliver DistlerODOliver Distler
- 29 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (5) , 1877-1886
Abstract
Objectives: To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods: A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results: Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions: Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.Keywords
Funding Information
- NIH
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24-AR-063120, 1R01-AR070470-01A1)
- NIAMS (AR007080)
This publication has 38 references indexed in Scilit:
- Management of Systemic-Sclerosis-Associated Interstitial Lung DiseaseRheumatic Disease Clinics of North America, 2015
- Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working GroupThe Journal of Rheumatology, 2015
- Interstitial lung disease in systemic sclerosisLa Presse Médicale, 2014
- Mortality and survival in systemic sclerosis: Systematic review and meta-analysisSeminars in Arthritis and Rheumatism, 2014
- Predictors of Mortality and Progression in Scleroderma-Associated Interstitial Lung DiseaseChest, 2014
- Prediction of Pulmonary Complications and Long‐Term Survival in Systemic SclerosisArthritis & Rheumatology, 2014
- Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) databaseAnnals of the Rheumatic Diseases, 2010
- Predictors of end stage lung disease in systemic sclerosisAnnals of the Rheumatic Diseases, 2003
- Severe restrictive lung disease in systemic sclerosisArthritis & Rheumatism, 1994
- High agreement but low kappa: II. Resolving the paradoxesJournal of Clinical Epidemiology, 1990